Knee surgery patients get bone marrow shot to halt arthritis
NCT ID NCT02582489
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether injecting a concentrated sample of a patient's own bone marrow into the knee right after meniscus surgery can slow down or prevent arthritis. One hundred adults with a torn meniscus will receive either the bone marrow injection or a saltwater placebo, and their knee function, pain, and imaging results will be tracked for a year. The goal is to see if this simple procedure can improve long-term outcomes after a common knee operation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Bone marrow aspirate concentrate (BMAC)
- What this could lead to
- If it works, this could point toward a way to slow or prevent osteoarthritis after knee surgery, potentially reducing pain and improving long-term knee function.
- What could go wrong
- This is a small, early-phase trial with only 100 participants. The treatment may not provide any benefit over a placebo, and the effects on osteoarthritis progression are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS POST-MENISCECTOMY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rush University Medical Center
Chicago, Illinois, 60612, United States